Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines-Reference-Cited by-同舟云学术

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

Published:2014-03-06 Issue:4 Volume:27 Page:590-600
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res.

Author:

Young Richard J.¹,Waldeck Kelly¹,Martin Claire¹,Foo Jung H.¹,Cameron Donald P.¹,Kirby Laura¹,Do Hongdo²³,Mitchell Catherine²,Cullinane Carleen¹⁴,Liu Wendy¹,Fox Stephen B.²⁴,Dutton-Regester Ken⁵,Hayward Nicholas K.⁵,Jene Nicholas²,Dobrovic Alexander²³⁴,Pearson Richard B.¹⁴⁶,Christensen James G.⁷,Randolph Sophia⁷,McArthur Grant A.¹⁴,Sheppard Karen E.¹⁴⁶

Affiliation:

1. Research Division; Peter MacCallum Cancer Centre; East Melbourne Vic. Australia

2. Pathology Department; Peter MacCallum Cancer Centre; East Melbourne Vic. Australia

3. Ludwig Institute for Cancer Research; Olivia Newton John Cancer and Wellness Centre; Melbourne Vic. Australia

4. Sir Peter MacCallum Department of Oncology; University of Melbourne; Parkville Vic. Australia

5. Oncogenomics Laboratory; QIMR Berghofer Medical Research Institute; Brisbane Qld Australia

6. Department of Biochemistry and Molecular Biology; University of Melbourne; Parkville Vic. Australia

7. Pfizer Global Research and Development; La Jolla Laboratories; San Diego CA USA

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcmr.12228/fullpdf

Reference40 articles.

1. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity;Barretina;Nature,2012

2. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med.,2011

3. Targeting cell cycle and hormone receptor pathways in cancer;Comstock;Oncogene,2013

4. Distinct sets of genetic alterations in melanoma;Curtin;N. Engl. J. Med.,2005

5. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors;Dean;Cell Cycle,2012

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present;Expert Opinion on Therapeutic Patents;2024-07-17

2. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment;Human Genomics;2024-05-31

3. Loss of p14 diminishes immunogenicity in melanoma via non‐canonical Wnt signaling by reducing the peptide surface density;Molecular Oncology;2024-05-28

4. A Fucose-Containing Sulfated Polysaccharide from Spatoglossum schröederi Potentially Targets Tumor Growth Rather Than Cytotoxicity: Distinguishing Action on Human Melanoma Cell Lines;Marine Biotechnology;2024-01-26

5. Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region: Differential Diagnosis and Therapeutic Implications;Cancers;2024-01-19